Fortrea and Omico Announce Collaboration to Advance Precision Oncology Research

Fortrea has partnered with Omico, an Australian organization specializing in precision oncology, to enhance precision oncology research. This collaboration will integrate Fortrea's drug development expertise with Omico's PrOSPeCT program, aiming to improve trial planning and patient access to biomarker-matched studies. The initiative will provide insights into patient populations, including genomic profiling and trial-matching capabilities, facilitating more efficient site selection for clinical studies.